程序性细胞死亡蛋白1及其配体通路在特发性炎症性肌病中的研究进展

doi:10.35541/cjd.20200431

Abstract

Abstract: 【Abstract】 After the specific binding of programmed death-1 （PD-1） to programmed death ligand 1（PD-L1）, the PD-1/PD-L1 complex can exert a co-suppressive/co-stimulatory immunoregulatory effect, which can inhibit the activation and proliferation of T cells and their cytokine secretion, and play a key role in tumor immunity, autoimmunity and immune tolerance. This review summarizes structures and regulatory mechanisms of the PD-1/PD-L1 signaling pathway, aimming to facilitate the understanding of immune pathogenesis of idiopathic inflammatory myopathies complicated by malignant tumors, and to seek potential therapeutic targets and diagnostic strategies.

Key words: Programmed cell death 1 receptor, Myositis, Neoplasms, Immune checkpoint inhibitors, Anti-transcription intermediary factor 1-γ antibody

Shih Yanting, Li Hao, Zheng Jie, Cao Hua. Programmed death-1/programmed death ligand-1 signaling pathway in idiopathic inflammatory myopathies[J]. Chinese Journal of Dermatology, 2022, 55(7): 633-636.doi:10.35541/cjd.20200431

References ［34］

［1］	Thompson C, Piguet V, Choy E. The pathogenesis of dermatomyositis［J］. Br J Dermatol, 2018,179（6）:1256⁃1262. doi: 10.1111/bjd.15607.
［2］	Wiendl H, Mitsdoerffer M, Schneider D, et al. Human muscle cells express a B7⁃related molecule, B7⁃H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies［J］. FASEB J, 2003,17（13）:1892⁃1894. doi: 10. 1096/fj.03⁃0039fje.
［3］	Xiaoyu D, Yunxia W, Qi F, et al. Expression of B7⁃homolog 1 in Polymyositis［J］. Ann Clin Lab Sci, 2011,41（2）:154⁃160.
［4］	Chen H, Peng Q, Yang H, et al. Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis［J］. J Rheumatol, 2018,45（6）:835⁃840. doi: 10.3899/jrheum.170544.
［5］	Schildberg FA, Klein SR, Freeman GJ, et al. Coinhibitory pathways in the B7⁃CD28 ligand⁃receptor family［J］. Immunity, 2016,44（5）:955⁃972. doi: 10.1016/j.immuni.2016.05.002.
［6］	Chen L, Flies DB. Molecular mechanisms of T cell co⁃stimulation and co⁃inhibition［J］. Nat Rev Immunol, 2013,13（4）:227⁃242. doi: 10.1038/nri3405.
［7］	Francisco LM, Sage PT, Sharpe AH. The PD⁃1 pathway in tolerance and autoimmunity［J］. Immunol Rev, 2010,236:219⁃242. doi: 10.1111/j.1600⁃065X.2010.00923.x.
［8］	Kuol N, Stojanovska L, Nurgali K, et al. PD⁃1/PD⁃L1 in disease［J］. Immunotherapy, 2018,10（2）:149⁃160. doi: 10.2217/imt⁃2017⁃0120.
［9］	Lind H, Gameiro SR, Jochems C, et al. Dual targeting of TGF⁃β and PD⁃L1 via a bifunctional anti⁃PD⁃L1/TGF⁃βRII agent: status of preclinical and clinical advances［J］. J Immunother Cancer, 2020,8（1）. doi: 10.1136/jitc⁃2019⁃000433.
［10］	Park BV, Freeman ZT, Ghasemzadeh A, et al. TGFβ1⁃mediated SMAD3 enhances PD⁃1 expression on antigen⁃specific T cells in cancer［J］. Cancer Discov, 2016,6（12）:1366⁃1381. doi: 10.1158/2159⁃8290.CD⁃15⁃1347.
［11］	Fantini MC, Becker C, Monteleone G, et al. Cutting edge: TGF⁃beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down⁃regulation of Smad7［J］. J Immunol, 2004,172（9）:5149⁃5153. doi: 10.4049/jimmunol.172. 9.5149.
［12］	Garo LP, Ajay AK, Fujiwara M, et al. Smad7 controls immunoregulatory PDL2/1⁃PD1 signaling in intestinal inflammation and autoimmunity［J］. Cell Rep, 2019,28（13）:3353⁃3366.e5. doi: 10.1016/j.celrep.2019.07.065.
［13］	Nishimura H, Nose M, Hiai H, et al. Development of lupus⁃like autoimmune diseases by disruption of the PD⁃1 gene encoding an ITIM motif⁃carrying immunoreceptor［J］. Immunity, 1999,11（2）:141⁃151. doi: 10.1016/s1074⁃7613（00）80089⁃8.
［14］	Greisen SR, Rasmussen TK, Stengaard⁃Pedersen K, et al. Increased soluble programmed death⁃1 （sPD⁃1） is associated with disease activity and radiographic progression in early rheumatoid arthritis［J］. Scand J Rheumatol, 2014,43（2）:101⁃108. doi: 10.3109/03009742.2013.823517.
［15］	Kobayashi M, Kawano S, Hatachi S, et al. Enhanced expression of programmed death⁃1 （PD⁃1）/PD⁃L1 in salivary glands of patients with Sjögren′s syndrome［J］. J Rheumatol, 2005,32（11）:2156⁃2163.
［16］	Dani L, Ian Che W, Lundberg IE, et al. Overall and site⁃specific cancer before and after diagnosis of idiopathic inflammatory myopathies: a nationwide study 2002-2016［J］. Semin Arthritis Rheum, 2021,51（1）:331⁃337. doi: 10.1016/j.semarthrit.2020.12. 009.
［17］	Hsu JL, Liao MF, Chu CC, et al. Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan［J］. Sci Rep, 2021,11（1）:4545. doi: 10.1038/s41598⁃021⁃83729⁃5.
［18］	Zidane M, Dressler C, Nast A, et al. Incidences of different cancer types in dermatomyositis, polymyositis and dermatopolymyositis: results of a registry analysis［J］. Br J Dermatol, 2020,183（1）:186⁃188. doi: 10.1111/bjd.18948.
［19］	Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody［J］. Brain, 2016,139（Pt 8）:2131⁃2135. doi: 10.1093/brain/aww054.
［20］	McHugh NJ, Tansley SL. Autoantibodies in myositis［J］. Nat Rev Rheumatol, 2018,14（5）:290⁃302. doi: 10.1038/nrrheum.2018.56.
［21］	De Vooght J, Vulsteke JB, De Haes P, et al. Anti⁃TIF1⁃γ autoantibodies: warning lights of a tumour autoantigen［J］. Rheumatology （Oxford）, 2020,59（3）:469⁃477. doi: 10.1093/rheumatology/kez572.
［22］	Aussy A, Boyer O, Cordel N. Dermatomyositis and immune⁃mediated necrotizing myopathies: a window on autoimmunity and cancer［J］. Front Immunol, 2017,8:992. doi: 10.3389/fimmu.2017.00992.
［23］	Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity′s roles in cancer suppression and promotion［J］. Science, 2011,331（6024）:1565⁃1570. doi: 10.1126/science. 1203486.
［24］	Labrador⁃Horrillo M, Selva⁃O′Callaghan A. Cancer⁃associated dermatomyositis: does the PD⁃1 checkpoint pathway play a role?［J］. J Rheumatol, 2018,45（6）:731⁃732. doi: 10.3899/jrheum. 180007.
［25］	Knauss S, Preusse C, Allenbach Y, et al. PD1 pathway in immune⁃mediated myopathies: pathogenesis of dysfunctional T cells revisited［J］. Neurol Neuroimmunol Neuroinflamm, 2019,6（3）:e558. doi: 10.1212/NXI.0000000000000558.
［26］	Pinal⁃Fernandez I, Ferrer⁃Fabregas B, Trallero⁃Araguas E, et al. Tumour TIF1 mutations and loss of heterozygosity related to cancer⁃associated myositis［J］. Rheumatology （Oxford）, 2018,57（2）:388⁃396. doi: 10.1093/rheumatology/kex413.
［27］	Yu C, Ding Z, Liang H, et al. The roles of TIF1γ in cancer［J］. Front Oncol, 2019,9:979. doi: 10.3389/fonc.2019.00979.
［28］	Wang L, Yang H, Lei Z, et al. Repression of TIF1γ by SOX2 promotes TGF⁃β⁃induced epithelial⁃mesenchymal transition in non⁃small⁃cell lung cancer［J］. Oncogene, 2016,35（7）:867⁃877. doi: 10.1038/onc.2015.141.
［29］	Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment［J］. J Am Acad Dermatol, 2020,82（2）:283⁃296. doi: 10.1016/j.jaad.2019.05.105.
［30］	Abril⁃Rodriguez G, Ribas A. SnapShot: immune checkpoint inhibitors［J］. Cancer Cell, 2017,31（6）:848⁃848.e1. doi: 10. 1016/j.ccell.2017.05.010.
［31］	Shah M, Tayar JH, Abdel⁃Wahab N, et al. Myositis as an adverse event of immune checkpoint blockade for cancer therapy［J］. Semin Arthritis Rheum, 2019,48（4）:736⁃740. doi: 10.1016/j.semarthrit.2018.05.006.
［32］	Fazel M, Jedlowski PM. Severe myositis, myocarditis, and myasthenia gravis with elevated anti⁃striated muscle antibody following single dose of ipilimumab⁃nivolumab therapy in a patient with metastatic melanoma［J］. Case Reports Immunol, 2019,2019:2539493. doi: 10.1155/2019/2539493.
［33］	Marano AL, Clarke JM, Morse MA, et al. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti⁃programmed cell death 1 therapy［J］. Br J Dermatol, 2019,181（3）:580⁃583. doi: 10.1111/bjd.17245.
［34］	Blank CU, Haining WN, Held W, et al. Defining ′T cell exhaustion′［J］. Nat Rev Immunol, 2019,19（11）:665⁃674. doi: 10.1038/s41577⁃019⁃0221⁃9.

[1]	Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 55(7): 603-609.
[2]	Zhang Shimin, Hu Yunyun, Zhao Xiaoqing, Du Lianjun, Cao Hua, Zheng Jie. Application of imaging techniques in diagnosis and severity assessment of dermatomyositis [J]. Chinese Journal of Dermatology, 2022, 55(7): 637-640.
[3]	Feng Hua, Gao Yingshu, Li Qing, Sun Lianwen. Cell mechanics in dermatology [J]. Chinese Journal of Dermatology, 2022, 55(7): 641-644.
[4]	Committee on Autoimmune Diseases, China Dermatologist Association. Cyclosporine in the treatment of immune-related skin diseases: an expert proposal [J]. Chinese Journal of Dermatology, 2022, 55(6): 471-479.
[5]	Wei Feng, Zhang Xiaoguang, Han Wenrui, Rong Rong, Wang Lijuan, Zhao Yike, Li Yanling. Efficacy of combined local flaps in repair of larger defects after Mohs micrographic surgery in 11 cases of nasal and perinasal non-melanoma skin cancers [J]. Chinese Journal of Dermatology, 2022, 0(4): 20210119-e20210119.
[6]	Li Yan, Zhang Xuanfen, Zhang Wenfang. Exploration of the effect of EphB2 inhibitors on cutaneous squamous cell carcinoma and their mechanisms of action based on Wnt/β-catenin signaling pathway [J]. Chinese Journal of Dermatology, 2022, 55(4): 321-328.
[7]	Xu Congcong, Chen Hao. The research progress of PI3K/Akt/mT0R signaling pathway in cutaneous squamous cell carcinoma [J]. Chinese Journal of Dermatology, 2022, 55(3): 264-267.
[8]	Lyu Ling, Lyu Xiaoyan. Dermatomyositis with malignancy: an update [J]. Chinese Journal of Dermatology, 2022, 55(3): 276-279.
[9]	Yue Chao, Luo Xianyan, Wang Tao, Duan Mengying, Dai Yeqin, Peng Jianzhong. Application of horizontal closure of longitudinal incisions in reconstructing pentagonal full-thickness defects of the lower eyelid margin [J]. Chinese Journal of Dermatology, 2022, 55(2): 159-161.
[10]	Yan Na, Yang Lijuan, Zhao Chan, Liu Yan, Zeng Weihui, Geng Songmei, Tan Xuanfeng. Application of tunneled subcutaneous pedicle flaps in repair of nasal alar defects [J]. Chinese Journal of Dermatology, 2022, 55(2): 161-163.
[11]	Cao Meng, Hong Anlan, Wang Yan, Fang Fang. Clinical progress in pediatric melanoma [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210158-e20210158.
[12]	Zou Meirong, Wang Sheng. Cutaneous immune-related adverse reactions induced by immune checkpoint inhibitors [J]. Chinese Journal of Dermatology, 2022, 0(1): 20201221-e20201221.
[13]	Wu Yuhao, Zhang Guolong, Wang Xiuli. Tertiary lymphoid structures in malignant melanoma [J]. Chinese Journal of Dermatology, 2021, 54(9): 827-830.
[14]	Liu Qian, Li Guohong, Chen Bingwei. A survey on quality of life and its influencing factors among patients with non-melanoma skin cancers [J]. Chinese Journal of Dermatology, 2021, 54(9): 819-821.
[15]	Wang Yifei, Geng Yi, Miao Qiuju, Song Hao, Xu Xiulian, Sun Jianfang. Clinicopathological analysis of ten cases of mucinous nevi [J]. Chinese Journal of Dermatology, 2021, 54(9): 804-807.

Programmed death-1/programmed death ligand-1 signaling pathway in idiopathic inflammatory myopathies

PDF

Knowledge

Abstract

Cite this article

share this article

References ［34］

Related Articles 15

Metrics

Comments

Recommended 10